Tyra Biosciences Dips 0.12% Amid Earnings Concerns

On April 4, 2025, Tyra Biosciences experienced a slight decline of 0.12% in pre-market trading, reflecting a minor adjustment in investor sentiment.

HC Wainwright has recently issued a series of updates on Tyra Biosciences, including a reaffirmation of its "buy" rating and a price target of $30.00 per share. The firm also provided earnings estimates for the company, projecting losses of $0.56, $0.58, and $0.60 per share for the first, second, and third quarters of 2025, respectively. These estimates suggest that Tyra Biosciences is expected to face financial challenges in the near term, which could influence investor decisions and market sentiment.

Despite the projected losses, HC Wainwright's continued support for Tyra Biosciences indicates confidence in the company's long-term prospects. The firm's positive outlook may help mitigate some of the negative impact of the earnings estimates on the stock price. Investors will be closely monitoring Tyra Biosciences' performance in the coming quarters to assess whether the company can meet or exceed these expectations.